In May, Tom Whitehead, co-founder of
the Emily Whitehead Foundation, traveled
to Long Beach, Calif., to participate in the
2019 PDA Cell and Gene Therapy Conference.
At the conference, he spoke in the opening
plenary about his family’s experience
with a CAR-T (chimeric antigen receptor)
cell therapy and how the treatment affects
the patient’s experience, both during and
after administration. In 2012, his daughter
Emily was the first child to receive
a CAR-T cancer treatment that totally
eradicated her cancer. She is currently
seven years cancer-free.
The Foundation thanks Michael Blackton,
the moderator of the panel, PDA
staff member Brooke Schneider, and the
entire PDA committee for the invitation
to participate, as well as ValSource for
sponsoring the session Tom spoke in!
For more information, visit the Emily Whitehead Foundation website.